Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Satralizumab reduces risk of severe NMOSD relapse

Publish date:: September 12, 2020

Key clinical point: Patients with NMOSD who receive treatment with satralizumab are less likely to have a severe relapse, compared with controls.

Major finding: The proportion of severe relapses was 19% in the satralizumab group and 35% in the placebo group.

Study details: A pooled intention-to-treat analysis of data for 178 participants in two studies.

Disclosures: Chugai/Roche funded the study. Dr. Kleiter has received compensation for consulting, speaking, or serving on advisory boards for Alexion, Biogen, Celgene, Merck, and Roche.

Citation:

Kleiter I, et al. MSVirtual2020. Abstract FC01.03.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,